Skip to search formSkip to main contentSkip to account menu

AG 014699

Known as: AG-014699, AG014699, PARP-1 inhibitor AG014699 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rucaparib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Highly Cited
2014
Highly Cited
2014
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
Rucaparib is a potent, orally available, small-molecule inhibitor of poly ADP-ribose polymerase (PARP) 1 and 2. Ongoing clinical… 
Highly Cited
2013
Highly Cited
2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Purposepoly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I… 
Highly Cited
2013
Highly Cited
2013
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for… 
Highly Cited
2013
Highly Cited
2013
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
The present studies examined viability and DNA damage levels in mammary carcinoma cells following PARP1 and CHK1 inhibitor drug… 
Review
2011
Review
2011
PARP inhibitor treatment in ovarian and breast cancer.
Highly Cited
2011
Highly Cited
2011
Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.
Pedal to the metal: Using inverse Diels-Alder catalyst free TCO/Tz cycloadditions, we were able to quickly and selectively… 
Highly Cited
2010
Highly Cited
2010
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
Background:Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour. Poly(ADP… 
Highly Cited
2009
Highly Cited
2009
Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
Purpose: High-risk neuroblastoma is characterized by poor survival rates, and the development of improved therapeutic approaches… 
2005
2005
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors
3065 Background: AG-014699 inhibits poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair. AG-014699 sensitizes cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)